AFM
ORIA

Anson Funds Management’s Orion Biotech Opportunities Corp. Class A Ordinary Share ORIA Stock Holding History

Anson Funds Management’s Portfolio ORIA Stock Details ORIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-75,000
Closed -$738K – 291
2022
Q3 		$738K Hold
75,000
– – 0.09% 176
2022
Q2 		$730K Hold
75,000
– – 0.07% 201
2022
Q1 		$731K Hold
75,000
– – 0.06% 213
2021
Q4 		$725K Hold
75,000
– – 0.07% 205
2021
Q3 		$737K Buy
+75,000
New +$732K 0.07% 227

Other funds holding ORIA

6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Anson Funds Management's ORIA Position: Q4 2022 in Review

Anson Funds Management sold out of Orion Biotech Opportunities Corp. Class A Ordinary Share (ORIA) in Q4 2022, closing a stake of 75,000 shares — an estimated $738K sold.

Anson Funds Management first reported a position in ORIA in Q3 2021 and held it in 5 quarters. The position peaked at $738K in Q3 2022. 51 funds tracked by Wall St. Rank hold ORIA as of Q4 2022.

  • Anson Funds Management reported no remaining Orion Biotech Opportunities Corp. Class A Ordinary Share position as of Q4 2022 after selling out during the quarter.
  • Anson Funds Management sold 75,000 Orion Biotech Opportunities Corp. Class A Ordinary Share shares in Q4 2022, an estimated $738K.
  • Anson Funds Management first reported a position in Orion Biotech Opportunities Corp. Class A Ordinary Share in Q3 2021 and held it in 5 quarters.
  • Anson Funds Management's Orion Biotech Opportunities Corp. Class A Ordinary Share position peaked at $738K in Q3 2022.
  • 51 funds tracked by Wall St. Rank held Orion Biotech Opportunities Corp. Class A Ordinary Share as of Q4 2022.

Based on Anson Funds Management's 13F filing for Q4 2022, filed 13 Feb 2023.